migraine epidemiology forecast

DelveInsight’s ‘Migraine— Epidemiology Forecast to 2034’ report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Migraine-Disease Understanding

Migraine is ranked globally as the seventh most disabling disease among all diseases (responsible for 2.9% of all years of life lost to disability/YLDs) and the leading cause of disability among all neurological disorders.

It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face; although symptoms usually include a severe throbbing recurring pain on one side of the head, yet in one-third of migraine attacks, both sides are found to be affected.

Migraine is classified by the nature of the attack and its frequency as chronic and episodic migraine. Episodic migraine is characterized by those with migraine who have 0–14 headache days per month, while chronic migraine is characterized by 15 or more headache days per month.

Migraine remains undiagnosed and undertreated in at least ~ 50% of patients, and less than 50% of migraine patients consult a physician.

Treatment can be acute or preventive. Acute treatment is initiated during an attack to alleviate pain and disability and to stop the progression of the attack. Preventive treatment is used when there exists a known headache trigger, such as exercise or sexual activity, and for patients who have limited time exposure to a trigger, such as high-altitude ascent or menstruation.

The overall dynamics of the Migraine market is anticipated to change in the coming years owing to the expected launch of emerging therapies and others are developing treatments for Migraine.

Migraine Epidemiology

The Migraine epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for the seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Migraine epidemiology segmented as Total Prevalence of Migraine, Prevalent Cases of Migraine based on severity, Gender specific Prevalence of Migraine, and Diagnosed Cases of Chronic and Episodic Migraine. The report includes the prevalent scenario of Migraine in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country Wise-Chronic Migraine Epidemiology

The epidemiology segment also provides the Migraine epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• In 2023, the prevalent population of Migraine in the 7MM was found to be ~119,233 cases.
• The total prevalent cases of Migraine in the US are expected to increase with a significant CAGR by 2034, from around 46,140k cases in 2023 in the US.
• Among the European countries, Germany (22%) had the highest prevalent population of Migraine, followed by Italy in 2023. On the other hand, Spain had the least prevalent population around 17% of Migraine in the same year.
• However, the prevalent cases of Migraine are expected to decrease in Germany and Japan attributed to decrease in country population and other factors.
• In Japan, among prevalent cases of Migraine, most cases were of Episodic Migraine (~16,331k) in 2023. While least were in Chronic Migraine around ~950k in the same year.
• Assessments as per DelveInsight’s analysts show that the majority of cases of Migraine are occupied by females in comparison to males. There were approximately ~11,535k male and ~34,605k female cases of Migraine in 2023 in the US.
• In EU4 and the UK, among diagnosed cases of Migraine, most cases were of Episodic Migraine (~15,839k) in 2023. While least were in Chronic Migraine around ~2,411k in the same year.

Scope of the Report

• Migraine report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
• Migraine Epidemiology Report and Model provides an overview of the risk factors and global trends of Migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Migraine in the seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Migraine
• The report provides the segmentation of the Migraine epidemiology by Total Prevalence of Migraine in the 7MM
• The report provides the segmentation of the Total Prevalence of Migraine, Prevalent Cases of Migraine based on severity, Gender specific Prevalence of Migraine, and Diagnosed Cases of Chronic and Episodic Migraine  in the 7MM

Report Highlights

• 10-year forecast of Migraine epidemiology
• 7MM Coverage
• Total Prevalent cases of Migraine
• Gender-specific Cases of Migraine
• Diagnosed Cases of Chronic and Episodic Migraine 

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Get a detailed overview of How the market will evolve in the upcoming years: Migraine Market

Key Questions Answered

• What will be the growth opportunities in the 7MM concerning the patient population about Migraine?
• What are the Key Findings of Migraine epidemiology across the 7MM, and which country will have the highest number of patients during the forecast period (2025-2034)?
• What would be the total number of patients with Migraine across the 7MM during the forecast period (2025-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2025-2034)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2025-2034)?
• What are the disease risk, burden, and unmet needs of Migraine?
• What are the currently available treatments for Migraine?

Reasons to buy

The Migraine Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Migraine market
• Quantify patient populations in the global Migraine market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Migraine therapeutics in each of the markets covered
• Understand the magnitude of Migraine population by its prevalent cases
• Understand the magnitude of Migraine population by its clinical manifestation of diagnosed cases of Chronic and Episodic Migraine 
• The Migraine epidemiology report and model was written and developed by Masters and PhD level epidemiologists
• The Migraine Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population